- Home
- LBGJ vs LGVN Comparison
LBGJ vs LGVN Comparison
Compare LBGJ & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LBGJ
- LGVN
- Stock Information
- Founded
- LBGJ 2007
- LGVN 2014
- Country
- LBGJ China
- LGVN United States
- Employees
- LBGJ N/A
- LGVN N/A
- Industry
- LBGJ
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- LBGJ
- LGVN Health Care
- Exchange
- LBGJ NYSE
- LGVN Nasdaq
- Market Cap
- LBGJ 24.7M
- LGVN 23.4M
- IPO Year
- LBGJ 2024
- LGVN 2021
- Fundamental
- Price
- LBGJ $1.49
- LGVN $1.31
- Analyst Decision
- LBGJ
- LGVN Strong Buy
- Analyst Count
- LBGJ 0
- LGVN 3
- Target Price
- LBGJ N/A
- LGVN $8.67
- AVG Volume (30 Days)
- LBGJ 72.0K
- LGVN 147.7K
- Earning Date
- LBGJ 06-17-2025
- LGVN 08-13-2025
- Dividend Yield
- LBGJ N/A
- LGVN N/A
- EPS Growth
- LBGJ N/A
- LGVN N/A
- EPS
- LBGJ N/A
- LGVN N/A
- Revenue
- LBGJ $11,781,015.00
- LGVN $2,225,000.00
- Revenue This Year
- LBGJ N/A
- LGVN N/A
- Revenue Next Year
- LBGJ N/A
- LGVN $51.48
- P/E Ratio
- LBGJ N/A
- LGVN N/A
- Revenue Growth
- LBGJ 21.82
- LGVN 127.50
- 52 Week Low
- LBGJ $1.02
- LGVN $1.14
- 52 Week High
- LBGJ $5.50
- LGVN $6.40
- Technical
- Relative Strength Index (RSI)
- LBGJ N/A
- LGVN 50.13
- Support Level
- LBGJ N/A
- LGVN $1.15
- Resistance Level
- LBGJ N/A
- LGVN $1.32
- Average True Range (ATR)
- LBGJ 0.00
- LGVN 0.09
- MACD
- LBGJ 0.00
- LGVN 0.01
- Stochastic Oscillator
- LBGJ 0.00
- LGVN 45.31
About LBGJ LI BANG INTERNATIONAL CORPORATION I
Li Bang International Corp Inc is a holding company. The firm through its subsidiaries engages in designing, developing, producing, and selling stainless steel commercial kitchen equipment in China under its own Libang brand. In addition, its subsidiaries provide customers with comprehensive services, from commercial kitchen design in the early stage to equipment installation and after-sales maintenance.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.